mmpc-logo mmpc-logo
twitter-logo    bluesky-logo
| Create Account | login
Publication
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic
Ovarian Syndrome.
Authors Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ
Submitted By Submitted Externally on 12/3/2021
Status Published
Journal The Journal of clinical endocrinology and metabolism
Year 2020
Date Published 1/1/2020
Volume : Pages 105 : Not Specified
PubMed Reference 31529097
Abstract Women with polycystic ovarian syndrome (PCOS) have decreased growth hormone
(GH), which can result in increased visceral adiposity (VAT) and impaired
vascular function. GH-releasing hormone, a dipeptidyl peptidase-4 (DPP4)
substrate, stimulates GH secretion., We tested the hypothesis that DPP4
inhibition increases GH and improves glucose levels and vascular function in
women with PCOS., Eighteen women with PCOS participated in a double-blind,
crossover study. They received sitagliptin either 100 mg or placebo daily for 1
month, with crossover treatments separated by an 8-week washout. During each
treatment, women underwent a 75-gram oral glucose tolerance test (OGTT) and
assessments of vascular function and body composition. Overnight GH secretion
was assessed via venous sampling every 10 minutes for 12 hours and analyzed
using an automated deconvolution algorithm., During OGTT, sitagliptin increased
glucagon-like peptide-1 (P < 0.001), early insulin secretion (from mean [± SD]
insulinogenic index 1.9 ± 1.2 to 3.2 ± 3.1; P = 0.02), and decreased peak
glucose (mean -17.2 mg/dL [95% CI, -27.7 to -6.6]; P < 0.01). At 1 month,
sitagliptin decreased VAT (from 1141.9 ± 700.7 to 1055.1 ± 710.1 g; P = 0.02)
but did not affect vascular function. Sitagliptin increased GH half-life (from
13.9 ± 3.6 to 17.0 ± 6.8 min, N = 16; P = 0.04) and interpulse interval (from
53.2 ± 20.0 to 77.3 ± 38.2 min, N = 16; P < 0.05) but did not increase mean
overnight GH (P = 0.92 vs placebo)., Sitagliptin decreased the maximal glucose
response to OGTT and VAT. Sitagliptin did not increase overnight GH but
increased GH half-life and the interpulse interval., This study was registered
at www.clinicaltrials.gov as NCT02122380 prior to enrollment of the first
participant.




Menu

Home
Contact
About MMPC
Animal Husbandry
Tests Data
Search Data
Analysis
Clients
MMPC Centers

Newsletter

Interested in receiving MMPC News?
twitter-logo Mouse Phenotyping
@NationalMMPC



2017 National MMPC. All Rights Reserved.